Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00

Edwards Lifesciences (NYSE:EW) had its target price raised by Royal Bank Of Canada from $89.00 to $95.00 in a research note published on Friday, MarketBeat.com reports. The brokerage currently has an outperform rating on the medical research company’s stock.

EW has been the topic of a number of other reports. Wells Fargo & Company upped their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Argus upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Mizuho upped their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday. Finally, William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $91.00.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $82.48 on Friday. The company’s 50-day moving average is $77.58 and its two-hundred day moving average is $76.97. Edwards Lifesciences has a 1-year low of $64.89 and a 1-year high of $87.09. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market capitalization of $48.42 billion, a price-to-earnings ratio of 11.87, a PEG ratio of 3.97 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the company earned $0.67 EPS. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Analysts forecast that Edwards Lifesciences will post 2.45 EPS for the current year.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the stock. Econ Financial Services Corp purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $889,000. Allspring Global Investments Holdings LLC lifted its position in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares during the last quarter. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $1,760,000. Czech National Bank lifted its position in shares of Edwards Lifesciences by 5.8% during the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock worth $11,214,000 after purchasing an additional 7,917 shares during the last quarter. Finally, Mirova US LLC lifted its position in shares of Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after purchasing an additional 1,054,301 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.